News: The Indian Council of Medical Research (ICMR) aims to develop a pediatric oral formulation of hydroxyurea to treat sickle cell disease (SCD) in India, where over 20 million individuals are affected.
Need and Importance
- Current Challenge: Hydroxyurea is typically available in 500 mg capsules or 200 mg tablets, posing difficulties in dosing for children.
- Importance: Crucial initiative aligns with the National Mission to eliminate Sickle Cell Anemia/SCD by 2047.
About Sickle Cell Disease (SCD):
- Definition: Genetic disorder altering red blood cell shape to sickle-shaped, causing complications like pain, anemia, and organ damage.
- Prevalence: Among the most common inherited blood disorders globally, impacting millions.
- Health Risks: Potential for severe issues such as stroke and organ failure.